Taysha gene therapies to participate in upcoming august investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivitol-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in a fireside chat for the btig virtual biotechnology conference and a panel for the 2021 wedbush pacgrow healthcare virtual conference. conferences detail
TSHA Ratings Summary
TSHA Quant Ranking